Hepatitis B and A vaccination in HIV-infected adults: A review

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 11, 2015, Pages 2582-2598

  Mena, G ^a   Garcia Basteiro A L ^b,c   Bayas, J M ^b,d  

^a HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^b CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^c Manhiça Health Research Center   (Mozambique)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Adults; Hepatitis A; Hepatitis B; HIV; Liver infection; Prevention; Vaccination

Indexed keywords

ALANINE AMINOTRANSFERASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE; VIRUS RNA;

ARTICLE; B LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL (TOPIC); FATIGUE; FEVER; HEPATITIS A; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MEN WHO HAVE SEX WITH MEN; MIXED INFECTION; MYALGIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; VACCINATION; VIRUS LOAD; ADULT; AGED; ANTIBODY PRODUCTION; COMPLICATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; SECONDARY IMMUNIZATION; TIME FACTOR; UTILIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODY FORMATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS B; HEPATITIS B VACCINES; HIV INFECTIONS; HUMANS; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84983456209     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1055424     Document Type: Article

References (130)

1. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): A multicohort collaboration. Lancet 2014;384:241-8.
2. Centers for Disease Control and Prevention CDC. CDC Features: World Hepatitis Day 2014-July 28th CDC Features. Atlanta: CDC; 2014 [updated July 2014]; Available at: http://www.cdc.gov/Fea tures/WorldHepatitisDay/
3. Centers for Disease Control and Prevention (CDC). HIV and Viral Hepatitis Fact Sheet. Atlanta: CDC; 2013 [updated March 2014]; Available at: http://www.cdc.gov/hiv/pdf/library_factsheets_HIV_and_ viral_Hepatitis.pdf
4. World Health Organization. Hepatitis A. Fact Sheet N_328. Geneva: WHO; 2008 [updated June 2014]; Available at: http://www.who.int/mediacentre/fact sheets/fs328/en/
5. Ida S, Tachikawa N, Nakajima A, Daikoku M, Yano M, Kikuchi Y, et al. Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection. Clin Infect Dis 2002;34:379-85.
6. Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 2005; 118(Supp10A):75S-83S.
7. Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan MJ. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect. Dis 2012;12:966-76.
8. Phung BC, Launay O. Vaccination against viral hepatitis of HIV-1 infected patients. Hum Vaccin Immunother 2012;8:554-9.
9. Ott J, Stevens G, Groeger J, Wiersma S. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212-9.
10. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al.; Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57:1-20.
11. WHO Regional Office for Europe. Management of hepatitis B and HIV coinfection. Clinical Protocol for the WHO European Region (2011 revision). Copenhagen: WHO, 2011 [accessed September 2014]. Available at: http://www.euro.who.int/__data/assets/pdf_file/0011/152012/e95792.pdf
12. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Mu~noz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-6.
13. Spradling PR, Richardson JT, Buchacz K, Moorman AC, Brooks JT. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007. J Viral Hepat 2010;17:879-86.
14. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009;49(5 Suppl): S138-45.
15. Alter MJ. Epidemiology of viral hepatitis and HIV coinfection. J Hepatol 2006;44(1 Suppl):S6-9.
16. Oliveira SB, Merch_an-Hamann E, Amorim LD. HIV/AIDS coinfection with the hepatitis B and C viruses in Brazil. Cad Saude Publica 2014;30:433-8.
17. Matthews PC, Geretti AM, Goulder PJR, Klenerman P. Epidemiology and impact of HIV coinfection with Hepatitis B and Hepatitis C viruses in Sub-Saharan Africa. J Clin Virol 2014;61:20-33.
18. Lee HC, Ko NY, Lee NY, Chang CM, Ko WC. Seroprevalence of viral hepatitis and sexually transmitted disease among adults with recently diagnosed HIV infection inSouthern Taiwan, 2000-2005: Upsurge in Hepatitis C virus infections among injection drug users. J Formos Med Assoc 2008;107:404-11.
19. Vento S, di Perri G, Luzzati R, Cruciani M, Garofano T, Mengoli C, et al. Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS. Lancet 1989;1:332-3.
20. Horvath J, Raffanti SP. Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Clin Infect Dis 1994;18:339-47.
21. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991;163:1138-40.
22. Bodsworth N, Donovan B, Nightingale BN. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989;160:577-82.
23. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, et al. Infuence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-10.
24. Sun HY, Sheng WH, Tsai MS, Lee KY, Chang SY, Hung CC. Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: A review. World J Gastroenterol 2014;20:14598-614.
25. Chun HM, Roediger MP, Hullsiek KH, Thio CL, Agan BK, Bradley WP, et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis 2012;205:185-93.
26. Eskild A, Magnus P, Petersen G, Sohlberg C, Jensen F, Kittelsen P, et al. Hepatitis B antibodies in HIVinfected homosexual men are associated with more rapid progression to AIDS. AIDS 1992;6:571-4.
27. Clifford GM, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B, et al. Influence of HIVrelated immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008;22:2135-41.
28. World Health Organization. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec 2009;84:405-20.
29. Centers for Disease Control and Prevention (CDC). Hepatitis B. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 13th ed, Hamborsky J, Kroger A, Wolfe S (Eds). Public Health Foundation, Washington, DC 2015 [accessed May 2014]. Available at: www.cdc.gov/vaccines/pubs/pinkbook/hepb.html
30. U.S. Department of Health and Human Servides. U. S. Food and Drug Administration (FDA). Vaccines, blood & biologics [accessed January 2015]. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vac cines/default.htm
31. European Medicines Agency (EMA). European public assessment reports (EPAR) for human medicines. [accessed January 2015]. Available at: http://www. ema.europa.eu/ema/
32. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J Infect Dis 1999;179:489-92.
33. Viviani S, Jack A, Hall AJ, Maine N, Mendy M, Montesano R, et al. Hepatitis B vaccination in infancy in The Gambia: Protection against carriage at 9 years of age. Vaccine 1999;17:2946-50.
34. Bialek SR, Bower WA, Novak R, Helgenberger L, Auerbach SB, Williams IT, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J 2008;27:881-5.
35. Keating GM, Noble S, Averhoff FM, Belloni C, Duval B, Goldwater PN, et al. Recombinant hepatitis B vaccine (Engerix-B®): A review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003;63:1021-51.
36. Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 2010;28:626-31.
37. Gunn TR, Bosley A, Woodfield DG. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates. N Z Med J 1989;102:1-3.
38. Ahmed S, Perveen I. Safety, Immunogenicity and reactogenicity of recombinant hepatitis B vaccine Engerix-B. Immunology 2011;135:81.
39. Niu MT, Rhodes P, Salive M, Lively T, Davis DM, Black S, et al. Comparative safety of two recombinant hepatitis B vaccines in children: Data from the vaccine adverse event reporting system (VAERS) and vaccine safety datalink (VSD). J Clin Epidemiol 1998;51:503-10.
40. Zahradnik JM, Couch RB, Gerin JL. Safety and immunogenicity of a purified hepatitis B virus vaccine prepared by using recombinant DNA technology. J Infect Dis 1987;155:903-8.
41. Schiff GM, Sherwood JR, Zeldis JB, Krause DS. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adolesc Health 1995;16:12-7.
42. Takaki A, Yagi T, Yasunaka T, Sadamori H, Shinoura S, Umeda Y, et al. Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation? J Gastroenterol 2013;48:1373-83.
43. Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012;107:1460-6.
44. Ni JD, Xiong YZ, Wang XJ, Xiu LC. Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis? Int J STD AIDS 2013;24:117-22.
45. Kim HN, Harrington RD, Crane HM, Dhanireddy S, Dellit TH, Spach DH. Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS 2009; 20:595-600.
46. Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005;23:2902-8.
47. Ungulkraiwit P, Jongjirawisan Y, Atamasirikul K, Sungkanuparph S. Factors for predicting successful immune response to hepatitis B vaccination in HIV-1 infected patients. Southeast Asian J Trop Med Public Health 2007;38:680-5.
48. Kim HN, Harrington RD, Van Rompaey SE, Kitahata MM. Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. Int J STD AIDS 2008;19:600-4.
49. Bailey CL, Smith V, Sands M. Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults. Int J Infect Dis 2008; 12:e77-83.
50. Psevdos G, Kim JH, Groce V, Sharp V. Efficacy of double-dose hepatitis B rescue vaccination in HIVinfected patients. AIDS Patient Care STDS 2010;24:403-7.
51. Pettit NN, DePestel DD, Malani PN, Riddell J III. Factors associated with seroconversion after standard dose hepatitis B vaccination and high-dose revaccination among HIV-infected patients. HIV Clin Trials 2010;11:332-9.
52. Launay O, van der Vliet D, Rosenberg AR, Michel M-L, Piroth L, Rey D, Colin de Verdi_ere N, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011;305:1432-40.
53. Chaiklang K, Wipasa J, Chaiwarith R, Praparattanapan J, Supparatpinyo K. Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIVinfected adults: A randomized, controlled trial. PLoS One 2013;8:e80409.
54. Rock C, de Barra E, Sadlier C, Kelly S, Dowling C, McNally C, et al. Impact of a new vaccine clinic on hepatitis B vaccine completion and immunological response rates in an HIV-positive cohort. J Infect Public Health 2013;6:173-8.
55. Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005;41:1045-8.
56. De Vries-Sluijs TE, Hansen BE, van Doornum GJ, Springeling T, Evertsz NM, de Man RA, et al. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 2008;197:292-4.
57. Cornejo-Juarez P, Volkow-Fernandez P, Escobedo-Lopez K, Vilar-Compte D, Ruiz-Palacios G, Soto-Ramirez LE. Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. AIDS Res Ther 2006;3:9.
58. Sasaki MD, Foccacia R, de Messias-Reason IJ. Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine 2003;21:4545-9.
59. Veiga AP, Casseb J, Duarte AJ. Humoral response to hepatitis B vaccination and its relationship with T CD45RAC (na€ıve) and CD45ROC (memory) subsets in HIV-1-infected subjects. Vaccine 2006;24:7124-8.
60. Potsch DV, Oliveira ML, Ginuíno C, Miguel JC, Oliveira SA, Silva EF, et al. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine 2010;28:1447-50.
61. Potsch DV, Camacho LA, Tuboi S, Villar LM, Miguel JC, Ginuíno C, et al. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. Vaccine 2012;30:5973-7.
62. Mena G, Llupi_a A, García-Basteiro AL, Díez C, León A, García F, et al. Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice. Vaccine 2012; 30:3703-9.
63. Overton ET, Kang M, Peters MG, Umbleja T, Alston-Smith BL, Bastow B, et al. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine 2010;28:5597-604.
64. Irungu E, Mugo N, Ngure K, Njuguna R, Celum C, Farquhar C, et al. Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya. J Infect Dis 2013;207:402-10.
65. Kim JH, Psevdos G, Groce V, Sharp V. Persistence of protective hepatitis B surface antibody titers after successful double-dose hepatitis B virus rescue vaccination in HIV-infected patients. Gut Liver 2012; 6:86-91.
66. Cruciani M, Mengoli C, Serpelloni G, Lanza A, Gomma M, Nardi S, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009;27:17-22.
67. De Vries-Sluijs TE, Hansen BE, van Doornum GJ, Springeling T, Evertsz NM, de Man RA, et al. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIVinfected patients. J Infect Dis 2008;197:292-4.
68. Zhao D-M, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4CCD25C T cells selectively kill B lymphocytes. Blood 2006;107:3925-32.
69. Goncalves L, Albarran B, Salmen S, Borges L, Fields H, Montes H, et al. The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology 2004;326:20-8.
70. Okoye AA, Picker LJ. CD4C T-Cell Depletion In HIV Infection: Mechanisms Of Immunological Failure. Immunol Rev 2013; 254:54-64.
71. Hazenberg MD, Hamann D, Schuitemaker H, Miedema F. T cell depletion in HIV-1 infection: how CD4C T cells go out of stock. Nat Immunol 2000;1:285-9.
72. Powis JE, Raboud J, Ostrowski M, Loutfy MR, Kovacs C, Walmsley SL. The Recombinant Hepatitis B Surface Antigen Vaccine in Persons With HIV: Is Seroconversion Sufficient for Long-term Protection? J Infect Dis 2012;205:1534-8.
73. Lopes VB, Hassing RJ, De Vries-Sluijs TEMS, El Barzouhi A, Hansen BE, Schutten M, et al. Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. Vaccine 2013;31:1040-4.
74. Titanji K, De Milito A, Cagigi A, Thorstensson R, Grützmeier S, Atlas A, et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 2006;108:1580-7.
75. Valour F, Cotte L, Voirin N, Godinot M, Ader F, Ferry T, et al. Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIVinfected patients. Vaccine 2014;32:4558-64.
76. Price H, Bansi L, Sabin CA, Bhagani S, Burroughs A, Chadwick D, et al. Hepatitis B Virus Infection in HIV-Positive Individuals in the UK Collaborative HIV Cohort (UK CHIC) Study. 2012;7:e49314.
77. Martins S, do Livramento A, Andrigueti M, Kretzer IF, Machado MJ, Spada C et al. Vaccination coverage and immunity against hepatitis B among HIVinfected patients in South Brazil. Braz J Infect Dis 2015;19:181-6.
78. Ho YL, Enohata T, Lopes MH, De Sousa Dos Santos S. Vaccination in Brazilian HIV-infected adults: a cross-sectional study. AIDS Patient Care STDS 2008;22:65-70.
79. Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009 Apr 10;58 (RR-4):1-207.
80. Geretti AM, BHIVA Immunization Writing Committee, Brook G, Cameron C, Chadwick D, Heyderman RS, et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008;9:795-848.
81. European AIDS Clinical Society. Clinical management and treatment of HIV-infected patients in Europe. V 7.1. November 2014. Zurich: EACS, 2014 [accessed December 2014]. Available at: http://www.eacsociety.org/files/guidelines-7.1-english.pdf.
82. World Health Organization. The Global Prevalence of Hepatitis A Virus Infection and Susceptibility: A Systematic Review. Geneva: WHO; 2010 [updated January 2015]; Available at: http://apps. who.int/iris/bitstream/10665/70180/1/WHOíV B_10.01_eng.pdf
83. Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L. Hepatitis A: Epidemiology and prevention in developing countries. World J Hepatol 2012;4:68-73.
84. Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev 2006;28:101-11.
85. Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010;28:6653-7.
86. Franco E, Giambi C, Ialacci R, Coppola RC, Zanetti AR. Risk groups for hepatitis A virus infection. Vaccine 2003; 21:2224-33.
87. Broman M, Jokinen S, Kuusi M, Lappalainen M, Roivainen M, Liitsola K, et al. Epidemiology of hepatitis A in Finland in 1990-2007. J Med Virol 2010;82:934-41.
88. WHO position paper on hepatitis A vaccines-June 2012. Wkly Epidemiol Rec 2012;87:261-76.
89. Fainboim H, Gonz_alez J, Fassio E, Martínez A, Otegui L, Eposto M, et al. Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study. J Viral Hepat 1999;6:53-7.
90. Costa-Mattioli M, Allavena C, Poirier A-S, Billaudel S, Raffi F, Ferr_e V. Prolonged hepatitis A infection in an HIV-1 seropositive patient. J Med Virol 2002;68:7-11.
91. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:286-90.
92. Sloan DS. The utilisation of hepatitis A vaccine 1992-1994. Health Bull (Edinb) 1996;54:140-51.
93. Samandari T, Bell BP, Armstrong GL. Quantifying the impact of hepatitis A immunization in the United States, 1995-2001. Vaccine 2004;22:4342-50.
94. Van Damme P, Van Herck K. A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. Expert Rev Vaccines 2004;3:249-67.
95. Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, PoopatanakoolW, Kozik CA, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271:1328-34.
96. Briem H, Safary A. Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later. J Med Virol 1994;44:443-5.
97. Zhang ZL, Zhu XJ, Shan AL, Gao ZG, Zhang Y, Ding YX, et al. Effectiveness of 10-year vaccination (2001-2010) on Hepatitis A in Tianjin, China. Hum Vaccin Immunother 2014;10:1008-12.
98. Bialek SR, Thoroughman DA, Hu D, Simard EP, Chattin J, Cheek J, et al. Hepatitis A incidence and hepatitis a vaccination among American Indians and Alaska Natives, 1990-2001. Am J Public Health 2004;94:996-1001.
99. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005;294:202-10.
100. Bian GL, Ma R, Dong HJ, Ni HX, Hu FJ, Chen YR, et al. Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children. Vaccine 2010;28:4798-801.
101. Raczniak GA, Bulkow LR, Bruce MG, Zanis CL, Baum RL, Snowball MM, et al. Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series. J Infect Dis 2013;207:493-6.
102. Raczniak GA, Thomas TK, Bulkow LR, Negus SE, Zanis CL, Bruce MG, et al. Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children. Vaccine 2013;31:2152-5.
103. Bovier PA, Bock J, Ebengo TF, Frösner G, Glaus J, Herzog C, et al. Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine. J Med Virol 2010;82:1629-34.
104. Demicheli V, Tiberti D. The effectiveness and safety of hepatitis A vaccine: a systematic review. Vaccine 2003;21:2242-5.
105. Black S, Shinefield H, Hansen J, Lewis E, Su L, Coplan P. A post-licensure evaluation of the safety of inactivated hepatitis A vaccine (VAQTA, Merck) in children and adults. Vaccine 2004;22:766-72.
106. Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:1-23.
107. Li RC, Li Y, Yi N, Huang L, Wan Z, Zhang Y, et al. An open, prospective, randomized study comparing the immunogenicity and safety of two inactivated hepatitis A pediatric vaccines in toddlers, children and adolescents in China. Pediatr Infect Dis J 2013;32: e77-81.
108. Wallace MR, Brandt CJ, Earhart KC, Kuter BJ, Grosso AD, Lakkis H, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIVinfected subjects. Clin Infect Dis 2004;39:1207-13.
109. Weissman S, Feucht C, Moore BA. Response to hepatitis A vaccine in HIV-positive patients. J Viral Hepat 2006;13:81-6.
110. Rimland D, Guest JL. Response to hepatitis A vaccine in HIV patients in the HAART era. AIDS 2005;19:1702-4.
111. Overton ET, Nurutdinova D, Sungkanuparph S, Seyfried W, Groger RK, Powderly WG. Predictors of immunity after hepatitis A vaccination in HIVinfected persons. J Viral Hepat 2007;14:189-93.
112. Launay O, Grabar S, Gordien E, Desaint C, Jegou D, Abad S, et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr 2008;49:272-5.
113. Crum-Cianflone NF, Wilkins K, Lee AW, Grosso A, Landrum ML, Weintrob A, et al. Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis 2011;203:1815-23.
114. Kourkounti S, Mavrianou N, Paparizos VA, Kyriakis K, Hatzivassiliou M, Kordosis T, et al. Immune response to hepatitis A vaccination in HIV-infected men in Greece. Int J STD AIDS 2012;23:464-7.
115. Tseng YT, Chang SY, Liu WC, Sun HY, Wu CH, Wu PY, et al. Comparative effectiveness of two doses versus three doses of hepatitis A vaccine in human immunodeficiency virus-infected and-uninfected men who have sex with men. Hepatology 2013;57:1734-41.
116. Jimenez HR, Hallit RR, Debari VA, Slim J. Hepatitis A vaccine response in HIV-infected patients: are TWINRIX and HAVRIX interchangeable? Vaccine 2013;31:1328-33.
117. Kourkounti S, Papaizos V, Leuow K, Kordosis T, Antoniou C. Hepatitis A vaccination and immunological parameters in HIV-infected patients. Viral Immunol 2013;26:357-63.
118. Jablonowska E, Kuydowicz J. Durability of response to vaccination against viral hepatitis A in HIVinfected patients: a 5-year observation. Int J STD AIDS 2014;25:745-50.
119. Mena G, Llupi_a A, García-Basteiro AL, Díez C, León A, García F, et al. Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice. Vaccine 2012; 30:3703-9.
120. Kemper CA, Haubrich R, Frank I, Dubin G, Buscarino C, McCutchan JA, et al. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a doubleblind, randomized, placebo-controlled trial. J Infect Dis 2003;187:1327-31.
121. Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4 Clymphocytes. AIDS 1994;8:469-76.
122. Gandhi RT, Wurcel A, Lee H, McGovern B, Shopis J, Geary M, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005;191:1435-41.
123. Armstrong KE, Bush HM, Collins JD, Feola DJ, Caldwell GC, Thornton AC. Role of CD4 count in immunity development after hepatitis A and B vaccination among HIV-infected patients: Kentucky, 2002-2007. J Int Assoc Physicians AIDS Care (Chic) 2010;9:179-86.
124. Winter AP, Follett EA, McIntyre J, Stewart J, Symington IS. Influence of smoking on immunological responses to hepatitis B vaccine. Vaccine 1994;12:771-2.
125. Kern_eis S, Desaint C, Brichler S, Rey D, Belarbi L, Gordien E et al. Long-term persistence of humoral immunity after hepatitis A vaccination in HIV infected adults. J Acquir Immune Defic Syndr 2011;57:e63-6.
126. Saksawad R, Likitnukul S, Warachit B, Hanvivatvong O, Poovorawan Y, Puripokai P. Immunogenicity and safety of a pediatric dose virosomal hepatitis A vaccine in Thai HIV-infected children. Vaccine 2011;29:4735-8.
127. Bodsworth NJ, Neilsen GA, Donovan B. The effect of immunization with inactivated hepatitis A vaccine on the clinical course of HIV-1 infection: 1-year followup. AIDS 1997;11:747-9.
128. Centers for Disease Control and Prevention (CDC). Hepatitis A. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 13th ed, Hamborsky J, Kroger A, Wolfe S (Eds). Public Health Foundation, Washington, DC 2015 [accessed May 2014]. Available at: www.cdc.gov/vaccines/pubs/pinkbook/hepa.html
129. Gov.UK. Chapter 18: Hepatitis B. In: Green Book: Immunisation against infectious disease, Salisbury D and Ramsay M (Eds). Public Health England, London, March 2013 [updated December 2013] [accessed September 2014]; Available at: https://www.gov.uk/government/publications/hepatitis-b-the-green-bookchapter-18
130. Overton E, Sungkanuparph S, Klebert M, Royal M, Demarco-Shaw D, Powderly W, et al. GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals. Open Virol J 2011;5:109-13.